The Pediatric Asthmatic

  • Christopher Chang


The incidence of allergies and asthma in the Western world has been increasing over the past 30 years. However, more recent data suggests that over the past 5–10 years, the overall global trends of asthma incidence have begun to stabilize (1). Urbanization and industrialization has contributed to the increase in developed countries, but the reasons for this are still unclear. Asthma is estimated to be responsible for 1 in every 250 deaths worldwide. Many of these deaths are preventable, and specific issues have been identified that may contribute to this high mortality rate. Factors that contribute to high ­mortality and morbidity include slow access to care and medications, inadequate environmental control of allergens and irritants, dietary changes, genetic variations, cultural barriers, lack of education amongst patients and providers, insufficient resources, and improper use of health care dollars.


Allergic Rhinitis Peak Flow Childhood Asthma Asthma Exacerbation Eosinophil Cationic Protein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Pearce N, Douwes J. The global epidemiology of asthma in children. Int J Tuberc Lung Dis 2006;10:125–32.PubMedGoogle Scholar
  2. 2.
    Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31:143–78.PubMedCrossRefGoogle Scholar
  3. 3.
    Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol 2007;120:S94–138.Google Scholar
  4. 4.
    Polk S, Sunyer J, Munoz-Ortiz L, et al. A prospective study of Fel d1 and Der p1 exposure in infancy and childhood wheezing. Am J Respir Crit Care Med 2004;170:273–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Wennergren G, Ekerljung L, Alm B, Eriksson J, Lotvall J, Lundback B. Asthma in late adolescence – farm childhood is protective and the prevalence increase has levelled off. Pediatr Allergy Immunol;21:806–13.Google Scholar
  6. 6.
    Sheehan WJ, Rangsithienchai PA, Wood RA, et al. Pest and allergen exposure and abatement in inner-city asthma: a work group report of the American Academy of Allergy, Asthma & Immunology Indoor Allergy/Air Pollution Committee. J Allergy Clin Immunol;125:575–81.Google Scholar
  7. 7.
    Chang C. The immune effects of naturally occurring and synthetic nanoparticles. J Autoimmun;34:J234–46.Google Scholar
  8. 8.
    Peroni DG, Pietrobelli A, Boner AL. Asthma and obesity in childhood: on the road ahead. Int J Obes (Lond);34:599–605.Google Scholar
  9. 9.
    Stickland MK, Spooner CH, Dryden DM, Rowe BH. The need for standardization in exercise ­challenge testing for exercise-induced asthma/bronchoconstriction. J Allergy Clin Immunol;126:878–80 e6.Google Scholar
  10. 10.
    Jackson DJ, Johnston SL. The role of viruses in acute exacerbations of asthma. J Allergy Clin Immunol;125:1178–87; quiz 88–9.Google Scholar
  11. 11.
    Bizzintino J, Lee WM, Laing IA, et al. Association between human rhinovirus C and severity of acute asthma in children. Eur Respir J. 2011;37:1037–42. Epub 2010 Aug 6.Google Scholar
  12. 12.
    Johnston SL, Pattemore PK, Sanderson G, et al. The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis. Am J Respir Crit Care Med 1996;154:654–60.PubMedGoogle Scholar
  13. 13.
    McBride JT. Pulmonary function changes in children after respiratory syncytial virus infection in infancy. J Pediatr 1999;135:28–32.PubMedCrossRefGoogle Scholar
  14. 14.
    Dimova-Yaneva D, Russell D, Main M, Brooker RJ, Helms PJ. Eosinophil activation and cysteinyl leukotriene production in infants with respiratory syncytial virus bronchiolitis. Clin Exp Allergy 2004;34:555–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Sigurs N, Gustafsson PM, Bjarnason R, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005;171:137–41.PubMedCrossRefGoogle Scholar
  16. 16.
    Sigurs N, Aljassim F, Kjellman B, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax 2010;65:1045–52. Epub 2010 Jun 27.Google Scholar
  17. 17.
    Gelfand EW, Cui ZH, Takeda K, Kanehiro A, Joetham A. Effects of fexofenadine on T-cell function in a murine model of allergen-induced airway inflammation and hyperresponsiveness. J Allergy Clin Immunol 2003;112:S89–95.PubMedCrossRefGoogle Scholar
  18. 18.
    Sapien RE, Fullerton-Gleason L, Allen N. Teaching school teachers to recognize respiratory distress in asthmatic children. J Asthma 2004;41:739–43.PubMedCrossRefGoogle Scholar
  19. 19.
    Mattes J, Storm van’s Gravesande K, Reining U, et al. NO in exhaled air is correlated with markers of eosinophilic airway inflammation in corticosteroid-dependent childhood asthma. Eur Respir J 1999;13:1391–5.Google Scholar
  20. 20.
    Bastain TM, Islam T, Berhane KT, et al. Exhaled nitric oxide, susceptibility and new-onset asthma in the children’s health study. Eur Respir J. 2011;37:523–31. Epub 2010 Jul 15.Google Scholar
  21. 21.
    Shields MD, Brown V, Stevenson EC, et al. Serum eosinophilic cationic protein and blood eosinophil counts for the prediction of the presence of airways inflammation in children with wheezing. Clin Exp Allergy 1999;29:1382–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Peona V, De Amici M, Quaglini S, et al. Serum eosinophilic cationic protein: is there a role in respiratory disorders? J Asthma;47:131–4.Google Scholar
  23. 23.
    Ahlstedt S. Clinical application of eosinophilic cationic protein in asthma. Allergy Proc 1995;16:59–62.PubMedCrossRefGoogle Scholar
  24. 24.
    Basyigit I, Yildiz F, Kacar Ozkara S, Boyaci H, Ilgazli A, Ozkarakas O. Effects of different anti-asthmatic agents on induced sputum and eosinophil cationic protein in mild asthmatics. Respirology 2004;9:514–20.Google Scholar
  25. 25.
    Kocak AK, Bor O, Yildiz B, Erdogan L, Us T. T-lymphocyte activation and the levels of eosinophilic cationic protein and interleukin-5 in asthmatic children with acute exacerbation and effect of glucocorticoid treatment. Allergy Asthma Proc 2006;27:371–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Randolph TG, Rollins JP. Adrenocorticotropic hormone (ACTH) its effect in bronchial asthma and ragweed hay fever. Ann Allergy 1950;8:149–62.PubMedGoogle Scholar
  27. 27.
    Allen DB, Mullen M, Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol 1994;93:967–76.PubMedCrossRefGoogle Scholar
  28. 28.
    Russell G. Childhood asthma and growth – a review of the literature. Respir Med 1994;88 Suppl A:31–6; discussion 6–7.Google Scholar
  29. 29.
    Chang CC, Tam AY. Suppression of adrenal function in children on inhaled steroids. J Paediatr Child Health 1991;27:232–4.PubMedCrossRefGoogle Scholar
  30. 30.
    Doull IJ, Freezer NJ, Holgate ST. Growth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropionate. Am J Respir Crit Care Med 1995;151:1715–9.PubMedGoogle Scholar
  31. 31.
    Boorsma M, Andersson N, Larsson P, Ullman A. Assessment of the relative systemic potency of inhaled fluticasone and budesonide. Eur Respir J 1996;9:1427–32.PubMedCrossRefGoogle Scholar
  32. 32.
    Lemanske RF, Jr., Busse WW. The US Food and Drug Administration and long-acting beta2-agonists: the importance of striking the right balance between risks and benefits of therapy? J Allergy Clin Immunol;126:449–52.Google Scholar
  33. 33.
    Alton EW, Norris AA. Chloride transport and the actions of nedocromil sodium and cromolyn sodium in asthma. J Allergy Clin Immunol 1996;98:S102–5; discussion S5–6.Google Scholar
  34. 34.
    Taylor IK, O’Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991;337:690–4.PubMedCrossRefGoogle Scholar
  35. 35.
    Kopriva F, Sobolova L, Szotkowska J, Zapalka M. Treatment of chronic cough in children with montelukast, a leukotriene receptor antagonist. J Asthma 2004;41:715–20.PubMedCrossRefGoogle Scholar
  36. 36.
    Ling M, Long AA. Pet dander and difficult-to-control asthma: Therapeutic options. Allergy Asthma Proc;31:385–91.Google Scholar
  37. 37.
    Shimizu T, Nishihira J, Watanabe H, Abe R, Ishibashi T, Shimizu H. Cetirizine, an H1-receptor antagonist, suppresses the expression of macrophage migration inhibitory factor: its potential anti-inflammatory action. Clin Exp Allergy 2004;34:103–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Charlesworth EN, Massey WA, Kagey-Sobotka A, Norman PS, Lichtenstein LM. Effect of H1 receptor blockade on the early and late response to cutaneous allergen challenge. J Pharmacol Exp Ther 1992;262:964–70.PubMedGoogle Scholar
  39. 39.
    D’Amato G, Liccardi G, Noschese P, Salzillo A, D’Amato M, Cazzola M. Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases. Curr Drug Targets Inflamm Allergy 2004;3:227–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Lewis RV, Lofthouse C. Adverse reactions with beta-adrenoceptor blocking drugs. An update. Drug Saf 1993;9:272–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol 1999;103:615–21.PubMedCrossRefGoogle Scholar
  42. 42.
    Ihre E, Larsson K. Airways responses to ipratropium bromide do not vary with time in asthmatic subjects. Studies of interindividual and intraindividual variation of bronchodilatation and protection against histamine-induced bronchoconstriction. Chest 1990;97:46–51.Google Scholar
  43. 43.
    Ueno O, Lee LN, Wagner PD. Effect of N-acetylcysteine on gas exchange after methacholine challenge and isoprenaline inhalation in the dog. Eur Respir J 1989;2:238–46.PubMedGoogle Scholar
  44. 44.
    Powell C, Chang C, Naguwa SM, Cheema G, Gershwin ME. Steroid induced osteonecrosis: An analysis of steroid dosing risk. Autoimmun Rev;9:721–43.Google Scholar
  45. 45.
    Bousquet J, Hejjaoui A, Clauzel AM, et al. Specific immunotherapy with a standardized Dermatophagoides pteronyssinus extract. II. Prediction of efficacy of immunotherapy. J Allergy Clin Immunol 1988;82:971–7.Google Scholar
  46. 46.
    Camargo CA, Jr., Smithline HA, Malice MP, Green SA, Reiss TF. A randomized controlled trial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med 2003;167:528–33.PubMedCrossRefGoogle Scholar
  47. 47.
    Ramsay CF, Pearson D, Mildenhall S, Wilson AM. Oral montelukast in acute asthma exacerbations: a randomised, double-blind, placebo-controlled trial. Thorax 2011;66:7–11. Epub 201 Oct 18.Google Scholar
  48. 48.
    Davis PA, Chang C, Hackman RM, Stern JS, Gershwin ME. Acupuncture in the treatment of asthma: a critical review. Allergol Immunopathol (Madr) 1998;26:263–71.Google Scholar
  49. 49.
    Li XM. Complementary and alternative medicine in pediatric allergic disorders. Curr Opin Allergy Clin Immunol 2009;9:161–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Singh D, Petavy F, Macdonald AJ, Lazaar AL, O’Connor BJ. The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Respir Res;11:26.Google Scholar
  51. 51.
    Coyle AJ, Page CP, Atkinson L, Sjoerdsma K, Touvay C, Metzger WJ. Modification of allergen-induced airway obstruction and airway hyperresponsiveness in an allergic rabbit model by the selective platelet-activating factor antagonist, BN 52021. J Allergy Clin Immunol 1989;84:960–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Szczeklik A, Schmitz-Schumann M, Krzanowski M, Virchow C, Sr. Delayed generation of thrombin in clotting blood of atopic patients with hayfever and asthma. Clin Exp Allergy 1991;21:411–5.PubMedCrossRefGoogle Scholar
  53. 53.
    Kameyoshi Y, Dorschner A, Mallet AI, Christophers E, Schroder JM. Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 1992;176:587–92.PubMedCrossRefGoogle Scholar
  54. 54.
    Tsicopoulos A, Lassalle P, Joseph M, et al. Effect of disodium cromoglycate on inflammatory cells bearing the Fc epsilon receptor type II (Fc epsilon RII). Int J Immunopharmacol 1988;10:227–36.PubMedCrossRefGoogle Scholar
  55. 55.
    Thorel T, Joseph M, Tsicopoulos A, Tonnel AB, Capron A. Inhibition by nedocromil sodium of IgE-mediated activation of human mononuclear phagocytes and platelets in allergy. Int Arch Allergy Appl Immunol 1988;85:232–7.PubMedCrossRefGoogle Scholar
  56. 56.
    De Vos C, Joseph M, Leprevost C, et al. Inhibition of human eosinophil chemotaxis and of the IgE-dependent stimulation of human blood platelets by cetirizine. Int Arch Allergy Appl Immunol 1989;88:212–5.PubMedCrossRefGoogle Scholar
  57. 57.
    Clifford RL, Knox AJ. Vitamin D – a new treatment for airway remodelling in asthma? Br J Pharmacol 2009;158:1426–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Palma-Carlos AG, Palma-Carlos ML, Santos MC, Melo A. Cytokines and adhesion molecules in respiratory allergy. Allerg Immunol (Paris) 1995;27:178–81.Google Scholar
  59. 59.
    Ciprandi G, Cadario G, Di Gioacchino GM, et al. Sublingual immunotherapy in children with allergic polysensitization. Allergy Asthma Proc;31:227–31.Google Scholar
  60. 60.
    Melen E, Himes BE, Brehm JM, et al. Analyses of shared genetic factors between asthma and obesity in children. J Allergy Clin Immunol;126:631–7 e1–8.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Division of Rheumatology, Allergy and Clinical Immunology, Department of Internal MedicineUniversity of California at DavisDavisUSA
  2. 2.Division of Allergy, Asthma and Immunology, Department of Pediatrics, Nemours Children’s HospitalThomas Jefferson UniversityWilmingtonUSA

Personalised recommendations